The Impact of Ramucirumab on Survival in @entity1 with XXXX : A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.

@entity1 @entity390 @entity3136 @entity548 @entity101 @entity5 @entity1295 @entity319 @entity1398 @entity1431 @entity99 @entity1054
BACKGROUND AND OBJECTIVES: Ramucirumab is a fully immunoglobulin G (lgG) monoclonal antibody targeting @entity319 ( @entity319 ). Previous clinical trials suggested ramucirumab could improve the survival and increase the risk of adverse effects. Here, we aimed to assess the efficacy and safety of ramucirumab in the treatment of advanced solid @entity5 . METHODS: Publications were searched from Pubmed, Embase database and clinicaltrials.gov. Hazard ratio (HR) and 95  % confidence interval (95  % CI) were calculated to evaluate efficacy, and the risk ratio (RR) for adverse effects. RESULTS: Ten relevant studies were included. Ramucirumab resulted in significant benefit in overall survival [OS, HR and 95  % CI 0.87 (0.82-0.93), I (2): 0.0  %] and progression-free survival [PFS, HR and 95  % CI 0.74 (0.66-0.82), I (2): 67.4  %]. Also the difference of @entity1054 ( @entity1054 ) and objective response rate (ORR) between two groups were also significant [0.70 (0.57-0.88) and 1.78 (1.40-2.25), respectively]. Ramucirumab could increase the risk of total adverse effects (TAEs, of any grade) by 1  % (from 0 to 2  %) and severe adverse effects (SAEs, grade  >  2) by 17  % (from 9 to 26  %). The most frequently occurring TAEs were @entity1295 (54.71  %), @entity1398 (42.74  %), @entity548 (37.55  %), @entity390 (34.63  %) and @entity3136 (33.74  %). Most frequently occurring SAEs (grade >= 3) were @entity1398 (33.43  %), @entity1295 (12.08  %), @entity1431 (10.59  %), @entity101 (8.99  %) and @entity99 (8.74  %). CONCLUSION: Ramucirumab could improve OS and PFS for @entity1 suffering from advanced solid @entity5 . Ramucirumab could increase the risk of TAEs and SAEs.
